Nkarta 3Q 2026: EPS ($0.45) — 10-Q Summary
Nkarta reported a wider net loss in 3Q 2026, with a loss of $33.33M compared to $21.72M a year earlier, due to increased R&D spending and lower interest income. R&D expenses rose to $29.5M, driven by higher program costs and clinical spending for NKX019. The company had $216.0M in cash and investments as of September 30, 2026, and is conducting clinical trials for NKX019 in various conditions.
How this was made

The 30-second read
Why it matters
The widened loss highlights higher cash burn, likely pressuring the stock in the near term.
Market read
First disclosure of Q3 2026 results; investors will reassess valuation based on loss magnitude and cash runway.
What to watch
Potential upcoming clinical data for NKX019 may offset short‑term loss concerns.
Background
Nkarta's 10‑Q provides detailed financials and updates on its NKX019 program.
Ticker impact
Nkarta filed its 10‑Q showing a widened net loss of $33.33M and EPS of -$0.45 for Q3 2026.
downward pressure as investors price in higher R&D spend and larger loss.
First‑time disclosure of a material loss increase; market typically reacts negatively to widening losses.
Market effects
Biotech sector may see broader risk‑off sentiment due to higher R&D burn rates.
U.S. small‑cap biotech investors may adjust exposure.
Limited to investors tracking U.S. biotech earnings.
Counterpoint
The cash runway of $216M could support future milestones, offering a buying opportunity at depressed prices.
Key entities
- companyNkarta, Inc.
U.S. biotech firm developing NKX019.
